BIIB up premarket on earnings report but I think the whole market might actually be disappointed that so little is being done to bolster BioGen's decaying pipeline. BioGen at least seems to have been able to steeply increase the price of its MS legacy drugs but that does not figure to be a sustainable strategy and really smoke and mirrors because the real price is negotiated with the Insurance Cos., Medicaid/care and Pharmacy benefit management. The market might see the paltry acquisition today as dangerous complacency of BioGen management with the state of its pipeline.
News 
Market Data 
Discover 
